Abstract Number: 0263 • ACR Convergence 2023
Patient, Disease, and Treatment Factors in Remission of Inflammatory Eye Disease
Background/Purpose: Noninfectious inflammatory eye disease (NIIED) is a sight-threatening condition with two-thirds of patients incurring prolonged vision loss due to uncontrolled ocular inflammation. Non-glucocorticoid systemic…Abstract Number: 1921 • ACR Convergence 2023
Clinical Spectrum of VEXAS Syndrome in a Rheumatology Department
Background/Purpose: VEXAS (vacuoles, E1 activating enzyme, X-linked, auto-inflammatory, somatic) syndrome is a clinically serious and potentially fatal adult-onset disease caused by somatic mutations in the…Abstract Number: 0270 • ACR Convergence 2023
Exploring the Potential of Oral Administration of 5-aminolevulinic Acid/sodium Ferrous Citrate in Adult-onset Still’s Disease: Preclinical Study in Mice and Pilot Investigation in Humans to Assess Efficacy and Safety
Background/Purpose: The primary objective of this study is to elucidate the therapeutic potential of 5-aminolevulinic acid/sodium ferrous citrate (5-ALA/SFC) in ameliorating the pathological manifestations associated…Abstract Number: 1924 • ACR Convergence 2023
Impact of the COVID-19 Pandemic on Clinical and Psychosocial Features of Patients with UCTD
Background/Purpose: The early COVID-19 pandemic led to physical and psychological burdens for patients with systemic rheumatic diseases, whether or not they had had COVID-19. To…Abstract Number: 0272 • ACR Convergence 2023
Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study
Background/Purpose: Susac syndrome (SuS) is a rare vasculitis affecting the brain, retina and inner ear in young women. Nonreversible hearing loss is the main long-term…Abstract Number: 1931 • ACR Convergence 2023
Anti-Ku Antibodies: A Case Series
Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs),…Abstract Number: 0281 • ACR Convergence 2023
Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?
Background/Purpose: Cystic fibrosis (CF) is characterized by mutations within the CFTR (cystic fibrosis transmembrane conductance regulator) gene that result in a defect of the chloride…Abstract Number: 1940 • ACR Convergence 2023
A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features
Background/Purpose: Patients with interstitial lung diseases (ILD) and clinical features of autoimmunity who do not satisfy the classification criteria for a specific autoimmune rheumatic disease…Abstract Number: 0340 • ACR Convergence 2023
Rheumatology Patients’ Experiences of a Nationwide Transition to an Adalimumab Biosimilar: A Cross-Sectional Study
Background/Purpose: Patients are frequently transitioned to biosimilars to reduce the cost burden of biologics. Brand changes can be daunting for patients who have concerns about…Abstract Number: 1941 • ACR Convergence 2023
Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations
Background/Purpose: There is limited information on VEXAS syndrome in the Latin-American population. We aimed to identify UBA1 mutations causing VEXAS syndrome in Mexican patients presenting…Abstract Number: 0713 • ACR Convergence 2023
IgG4-Related Disease as a Potencial Etiology of Idiopathic Constrictive Pericarditis
Background/Purpose: Constrictive pericarditis (CP) is a type of diastolic heart failure characterized by impaired cardiac filling due to the presence of an inelastic pericardium. Histologically,…Abstract Number: 1942 • ACR Convergence 2023
Prevalence and Screening Strategy for Latent Tuberculosis Infection in Patients with Rheumatic Immune-Mediated Diseases
Background/Purpose: Patients with rheumatic immune-mediated inflammatory diseases (rheumatic-IMID) with latent tuberculosis infection (LTBI) requiring biologic therapy (BT) are at anincreased risk of developing active tuberculosis…Abstract Number: 1004 • ACR Convergence 2023
Telerheumatology Shared-Care Model: Leveraging the Expertise of an ACPAC-Trained Extended Role Practitioner (ERP) in Rural-Remote Ontario
Background/Purpose: A shortage of Rheumatologists has led to gaps in inflammatory arthritis (IA) care in Canada. Amplified in rural-remote communities, the number of Rheumatologists practicing…Abstract Number: 2520 • ACR Convergence 2023
Identification of Clinical Phenotypes in Sarcoidosis Using a Cluster Analysis
Background/Purpose: Sarcoidosis is a disease with heterogeneous clinical presentation and course. The objective of this study is the identification of clinical phenotypes using cluster analysis.…Abstract Number: 1005 • ACR Convergence 2023
Telemedicine for Rheumatology Care: A Randomized, Single-Blind, Parallel Group, Noninferiority Trial
Background/Purpose: In the wake of the COVID-19 pandemic, telemedicine rapidly became standard of care for people with rheumatic diseases. Observational data on effectiveness and acceptability…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 8
- Next Page »